Fda News Briefs

FDA Approves Lilly’s New Oral Combo Pill for Common Breast Cancer Mutation. The Eli Lilly corporate headquarters in Indianapolis, IN, on August 15, 2024. AJ Mast/Bloomberg via Getty Images The FDA approved a new oral combo drug for a common breast cancer mutation on September 18. The treatment includes Inluriyo (imlunestrant) taken with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutation that has spread after hormone therapy. Results from a trial show that among 159 participants with ESR1 mutations, those taking the combination went a median of 11.1 months before their cancer spread,.

FDA Issues Class II Blood Pressure Medication Recall, Over 13,000 Bottles Affected. The FDA initiated a second recall of its 25 mg chlorthalidone tablets this year, bringing the total to more than 25,000 bottles. Anastasiia Sienotova/Getty Images 13,567 bottles of 25 mg chlorthalidone tablets were recalled after failing lab tests, according to the FDA. It’s the manufacturer’s second recall of the tablets this year, all with the same expiration date. Together, the two Class II recalls cover 25,027 bottles, according to FDA enforcement reports. Some people taking a common blood pressure medication may have pills that don’t dissolve the way.